Press coverage about DaVita HealthCare Partners (NYSE:DVA) has trended somewhat positive on Friday, according to AlphaOne Sentiment. The research firm, a unit of Accern, scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. DaVita HealthCare Partners earned a media sentiment score of 0.14 on AlphaOne’s scale. AlphaOne also gave media stories about the company an impact score of 66 out of 100, indicating that recent news coverage is likely to have an effect on the stock’s share price in the near term.
These are some of the media stories that may have impacted AlphaOne Sentiment’s scoring:
- Health-Care Investors Are in Denial (finance.yahoo.com)
- DBJ’s best of the week for June 10-16: Inside the Amazon and ViaWest deals, hospital merger talks and more (finance.yahoo.com)
- DaVita HealthCare Partners Inc. (DVA) Receives Average Rating of “Hold” from Brokerages (americanbankingnews.com)
- Insider Activity – DaVita Inc. Common Stock (NYSE:DVA) (highlightpress.com)
- DaVita Clinical Research Launches Alliance Site Network for Early Stage CKD Trials (finance.yahoo.com)
Several brokerages have commented on DVA. Jefferies Group LLC set a $70.00 price target on DaVita HealthCare Partners and gave the stock a “buy” rating in a research note on Friday, May 26th. Goldman Sachs Group, Inc. (The) reaffirmed a “sell” rating and issued a $62.00 target price on shares of DaVita HealthCare Partners in a research report on Thursday, May 25th. Zacks Investment Research downgraded DaVita HealthCare Partners from a “buy” rating to a “hold” rating in a research report on Wednesday, April 19th. TheStreet raised DaVita HealthCare Partners from a “c+” rating to a “b-” rating in a research report on Monday, April 3rd. Finally, Royal Bank of Canada reaffirmed a “hold” rating and issued a $62.00 target price on shares of DaVita HealthCare Partners in a research report on Friday, February 17th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company. DaVita HealthCare Partners has an average rating of “Hold” and a consensus target price of $69.50.
Shares of DaVita HealthCare Partners (NYSE:DVA) traded up 0.93% on Friday, reaching $66.17. The company had a trading volume of 1,774,123 shares. The firm has a market capitalization of $12.88 billion, a PE ratio of 10.87 and a beta of 1.00. The company has a 50-day moving average price of $65.71 and a 200-day moving average price of $66.06. DaVita HealthCare Partners has a 52-week low of $54.50 and a 52-week high of $78.77.
DaVita HealthCare Partners (NYSE:DVA) last posted its quarterly earnings data on Tuesday, May 2nd. The company reported $0.79 EPS for the quarter, missing analysts’ consensus estimates of $0.82 by $0.03. The business had revenue of $3.70 billion during the quarter, compared to the consensus estimate of $3.69 billion. DaVita HealthCare Partners had a return on equity of 14.85% and a net margin of 8.28%. Equities research analysts forecast that DaVita HealthCare Partners will post $3.54 EPS for the current fiscal year.
In other news, Director Charles Berg sold 8,414 shares of DaVita HealthCare Partners stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $65.80, for a total value of $553,641.20. Following the transaction, the director now directly owns 34,719 shares in the company, valued at $2,284,510.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Javier Rodriguez sold 1,294 shares of DaVita HealthCare Partners stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $66.21, for a total value of $85,675.74. Following the completion of the transaction, the chief executive officer now owns 99,111 shares in the company, valued at $6,562,139.31. The disclosure for this sale can be found here. Insiders sold 22,702 shares of company stock worth $1,495,492 over the last quarter. 2.10% of the stock is currently owned by corporate insiders.
About DaVita HealthCare Partners
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.